David Fiorentino, MD, PhD

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Higgs, B. W., Zhu, W., Morehouse, C., White, W. I., Brohawn, P., & Yao, Y. (2014). A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. ANNALS OF THE RHEUMATIC DISEASES, 73(1), 256-262.

The plasma cell signature in autoimmune disease.
Streicher, K., Morehouse, C. A., Groves, C. J., Rajan, B., Pilataxi, F., & Ranade, K. (2014). The plasma cell signature in autoimmune disease. Arthritis & rheumatology (Hoboken, N.J.), 66(1), 173-184.

Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?.
Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., & Casciola-Rosen, L. (2013). Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?. Arthritis and rheumatism, 65(11), 2954-2962.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?.
Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., & Casciola-Rosen, L. (2013). Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?. Arthritis and rheumatism, 65(11), 2954-2962.

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
Strand, V., Fiorentino, D., Hu, Cc., Day, R. M., Stevens, R. M., & Papp, K. A. (2013). Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. HEALTH AND QUALITY OF LIFE OUTCOMES, 11.

Localized cutaneous fibrosing disorders.
Yaqub, A., Chung, L., Rieger, K. E., & Fiorentino, D. F. (2013). Localized cutaneous fibrosing disorders. Rheumatic diseases clinics of North America, 39(2), 347-364.

Localized Cutaneous Fibrosing Disorders
Yaqub, A., Chung, L., Rieger, K. E., & Fiorentino, D. F. (2013). Localized Cutaneous Fibrosing Disorders. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 39(2), 347-?.

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases
de Souza, A., Ali-Shaw, T., Reddy, S. M., Fiorentino, D., & Strober, B. E. (2013). Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. BRITISH JOURNAL OF DERMATOLOGY, 168(1), 210-212.

Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey.
Linos, E., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2013). Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis research & therapy, 15(1), R7-?.

Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey
Linos, E., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2013). Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. ARTHRITIS RESEARCH & THERAPY, 15(1).

Genomic signatures characterize leukocyte infiltration in myositis muscles
Zhu, W., Streicher, K., Shen, N., Higgs, B. W., Morehouse, C., & Yao, Y. (2012). Genomic signatures characterize leukocyte infiltration in myositis muscles. BMC MEDICAL GENOMICS, 5.

Skin disease in dermatomyositis
Zaba, L. C., & Fiorentino, D. F. (2012). Skin disease in dermatomyositis. CURRENT OPINION IN RHEUMATOLOGY, 24(6), 597-601.

Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients.
Fiorentino, D., Chung, L., Zaba, L., Lingala, B., Rosen, A., & Casciola-Rosen, L. (2012). Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients. ARTHRITIS AND RHEUMATISM, 64(10), S828-S828.

Clinical presentation and evaluation of dermatomyositis.
Marvi, U., Chung, L., & Fiorentino, D. F. (2012). Clinical presentation and evaluation of dermatomyositis. Indian journal of dermatology, 57(5), 375-381.

Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab
Sarin, K. Y., & Fiorentino, D. (2012). Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab. ARCHIVES OF DERMATOLOGY, 148(9), 990-992.

Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI
Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., & Mosmann, T. R. (2012). Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI. JOURNAL OF IMMUNOLOGY, 189(5), 1230-1234.

A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies Report of 2 Cases and Review of the Literature
Chaisson, N. F., Paik, J., Orbai, A.-M., Casciola-Rosen, L., Fiorentino, D., & Rosen, A. (2012). A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies Report of 2 Cases and Review of the Literature. MEDICINE, 91(4), 220-228.

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
Strand, V., Sharp, V., Koenig, A. S., Park, G., Shi, Y., & Fiorentino, D. (2012). Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. ANNALS OF THE RHEUMATIC DISEASES, 71(7), 1143-1150.

Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection
Fiorentino, D., & Casciola-Rosen, L. (2012). Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. ARTHRITIS AND RHEUMATISM, 64(2), 346-349.

Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients
Higgs, B. W., Zhu, W., Richman, L., Fiorentino, D. F., Greenberg, S. A., & Yao, Y. (2012). Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 15(1), 25-35.

Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
Wong, D., Kea, B., Pesich, R., Higgs, B. W., Zhu, W., & Fiorentino, D. (2012). Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases. PLOS ONE, 7(1).

Consensus Guidelines for the Management of Plaque Psoriasis
Hsu, S., Papp, K. A., Lebwohl, M. G., Bagel, J., Blauvelt, A., & Bebo, B. F. (2012). Consensus Guidelines for the Management of Plaque Psoriasis. ARCHIVES OF DERMATOLOGY, 148(1), 95-102.

Quality of life in dermatomyositis
Goreshi, R., Chock, M., Foering, K., Feng, R., Okawa, J., & Werth, V. (2011). Quality of life in dermatomyositis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(6), 1107-1116.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway
Higgs, B. W., Liu, Z., White, B., Zhu, W., White, W. I., & Yao, Y. (2011). Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. ANNALS OF THE RHEUMATIC DISEASES, 70(11), 2029-2036.

Tyrosine kinases in inflammatory dermatologic disease
Paniagua, R. T., Fiorentino, D. F., Chung, L., & Robinson, W. H. (2011). Tyrosine kinases in inflammatory dermatologic disease. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(2), 389-403.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study
Fiorentino, D., Chung, L., Zwerner, J., Rosen, A., & Casciola-Rosen, L. (2011). The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(1), 25-34.

Pathogenesis of dermatomyositis: role of cytokines and interferon.
Kao, L., Chung, L., & Fiorentino, D. F. (2011). Pathogenesis of dermatomyositis: role of cytokines and interferon. Current rheumatology reports, 13(3), 225-232.

Prevalence of Children with Severe Fetal Alcohol Spectrum Disorders in Communities Near Rome, Italy: New Estimated Rates Are Higher than Previous Estimates
May, P. A., Fiorentino, D., Coriale, G., Kalberg, W. O., Hoyme, H. E., & Ceccanti, M. (2011). Prevalence of Children with Severe Fetal Alcohol Spectrum Disorders in Communities Near Rome, Italy: New Estimated Rates Are Higher than Previous Estimates. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 8(6), 2331-2351.

The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes
Fiorentino, D. F., Chen, R. O., STEWART, D. B., Brown, K. K., & Sundram, U. N. (2011). The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. BRITISH JOURNAL OF DERMATOLOGY, 164(5), 996-1003.

International consensus for a definition of disease flare in lupus
Ruperto, N., HANRAHAN, L. M., Alarcon, G. S., Belmont, H. M., Brey, R. L., & Merrill, J. T. (2011). International consensus for a definition of disease flare in lupus. LUPUS, 20(5), 453-462.

A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris
Fiorentino, D. F., Garcia, M. S., Rehmus, W., & Kimball, A. B. (2011). A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris. ARCHIVES OF DERMATOLOGY, 147(1), 117-118.

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.
Arefiev, K., Fiorentino, D. F., & Chung, L. (2011). Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. International journal of rheumatology, 2011, 201787-?.

Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument
Yassaee, M., Fiorentino, D., Okawa, J., Taylor, L., Coley, C., & Werth, V. P. (2010). Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. BRITISH JOURNAL OF DERMATOLOGY, 162(3), 669-673.

Conditioned Pharmacotherapeutic Effects: A Preliminary Study
Ader, R., Mercurio, M. G., Walton, J., James, D., Davis, M., & Fiorentino, D. (2010). Conditioned Pharmacotherapeutic Effects: A Preliminary Study. PSYCHOSOMATIC MEDICINE, 72(2), 192-197.

Treatment recommendations for psoriatic arthritis
Ritchlin, C. T., Kavanaugh, A., Gladman, D. D., Mease, P. J., Helliwell, P., & Taylor, W. J. (2009). Treatment recommendations for psoriatic arthritis. ANNALS OF THE RHEUMATIC DISEASES, 68(9), 1387-1394.

MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial
Chung, L., Shapiro, L., Fiorentino, D., Baron, M., Shanahan, J., & Wigley, F. M. (2009). MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial. ARTHRITIS AND RHEUMATISM, 60(3), 870-877.

Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis
Chung, L., Fiorentino, D. F., Benbarak, M. J., Adler, A. S., Mariano, M. M., & Robinson, W. H. (2009). Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis. ARTHRITIS AND RHEUMATISM, 60(2), 584-591.

Imatinib in the Treatment of Nephrogenic Systemic Fibrosis
Chandran, S., Petersen, J., Jacobs, C., Forentino, D., Doeden, K., & Lafayette, R. A. (2009). Imatinib in the Treatment of Nephrogenic Systemic Fibrosis. AMERICAN JOURNAL OF KIDNEY DISEASES, 53(1), 129-132.

Type I Interferon in the Induction or Exacerbation of Dermatomyositis What This Observation Tells Us About the Naturally Occurring Disease
Fiorentino, D. F. (2008). Type I Interferon in the Induction or Exacerbation of Dermatomyositis What This Observation Tells Us About the Naturally Occurring Disease. ARCHIVES OF DERMATOLOGY, 144(10), 1379-1382.

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis
Klein, R. Q., Bangert, C. A., Costner, M., Connolly, M. K., Tanikawa, A., & Werth, V. P. (2008). Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. BRITISH JOURNAL OF DERMATOLOGY, 159(4), 887-894.

Molecular framework for response to imatinib mesylate in systemic sclerosis
Chung, L., Fiorentino, D. F., Benbarak, M. J., Adler, A. S., Mariano, M. M., & Robinson, W. H. (2008). Molecular framework for response to imatinib mesylate in systemic sclerosis. ARTHRITIS AND RHEUMATISM, 58(9), S819-S820.

Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis
Hantash, B. M., Chiang, D., Kohler, S., & Fiorentino, D. (2008). Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 58(4), 661-664.

Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?
Fleming, J. N., Nash, R. A., McLeod, D. O., Fiorentino, D. F., Shulman, H. M., & Schwartz, S. M. (2008). Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?. PLOS ONE, 3(1).

Localized scleroderma and systemic sclerosis: Is there a connection?
Gupta, R. A., & Fiorentino, D. (2007). Localized scleroderma and systemic sclerosis: Is there a connection?. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 21(6), 1025-1036.

Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis
Richmond, H., Zwerner, J., Kim, Y., & Fiorentino, D. (2007). Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis. ARCHIVES OF DERMATOLOGY, 143(8), 1025-1030.

Mycophenolate mofetil
Zwerner, J., & Fiorentino, D. (2007). Mycophenolate mofetil. DERMATOLOGIC THERAPY, 20(4), 229-238.

A pilot trial of rituximab in the treatment of patients with dermatomyositis
Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763-767.

Comparison of the reliability & validity of outcome instruments for cutaneous dermatomyositis
Quain, R. D., Bangert, C. C., Costner, M., Connolly, M. K., Dugan, E., & Werth, V. P. (2007). Comparison of the reliability & validity of outcome instruments for cutaneous dermatomyositis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 127, S59-S59.

Update on cutaneous vasculitis
Grzeszkiewicz, T. M., & Fiorentino, D. F. (2006). Update on cutaneous vasculitis. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 25(4), 221-225.

Successful use of rituximab for cutaneous vasculitis
Chung, L., Funke, A. A., Chakravarty, E. F., Callen, J. P., & Fiorentino, D. F. (2006). Successful use of rituximab for cutaneous vasculitis. ARCHIVES OF DERMATOLOGY, 142(11), 1407-1410.

Systemic and locatized scleroderma
Chung, L., Lin, J., Furst, D. E., & Fiorentino, D. (2006). Systemic and locatized scleroderma. CLINICS IN DERMATOLOGY, 24(5), 374-392.

Epidemiology of FASD in a province in Italy: Prevalence and characteristics of children in a random sample of schools
May, P. A., Fiorentino, D., Gossage, J. P., Kalberg, W. O., Hoyme, H. E., & Ceccanti, M. (2006). Epidemiology of FASD in a province in Italy: Prevalence and characteristics of children in a random sample of schools. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 30(9), 1562-1575.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis
Chung, L., & Fiorentino, D. (2006). A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 54(5), 880-882.

Digital ulcers in patients with systemic sclerosis
Chung, L., & Fiorentino, D. (2006). Digital ulcers in patients with systemic sclerosis. AUTOIMMUNITY REVIEWS, 5(2), 125-128.

Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil
Hantash, B., & Fiorentino, D. (2006). Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. ARCHIVES OF DERMATOLOGY, 142(1), 109-110.

Muir-Torre syndrome: Confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions
Fiorentino, D. F., Nguyen, J. C., Egbert, B. M., & Swetter, S. M. (2004). Muir-Torre syndrome: Confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 50(3), 476-478.

Cutaneous vasculitis
Fiorentino, D. F. (2003). Cutaneous vasculitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 48(3), 311-340.

Characterization of Saccharomyces cerevisiae dna2 mutants suggests a role for the helicase late in S phase
Fiorentino, D. F., & Crabtree, G. R. (1997). Characterization of Saccharomyces cerevisiae dna2 mutants suggests a role for the helicase late in S phase. MOLECULAR BIOLOGY OF THE CELL, 8(12), 2519-2537.

The mechanism of action of cyclosporin A and FK506
Ho, S., Clipstone, N., Timmermann, L., Northrop, J., Graef, I., & Crabtree, G. R. (1996). The mechanism of action of cyclosporin A and FK506. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 80(3), S40-S45.

TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN
Zheng, X. F., Fiorentino, D., Chen, J., Crabtree, G. R., & Schreiber, S. L. (1995). TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN. CELL, 82(1), 121-130.

IMMUNOPHILINS INTERACT WITH CALCINEURIN IN THE ABSENCE OF EXOGENOUS IMMUNOSUPPRESSIVE LIGANDS
Cardenas, M. E., Hemenway, C., Muir, R. S., Ye, R., Fiorentino, D., & Heitman, J. (1994). IMMUNOPHILINS INTERACT WITH CALCINEURIN IN THE ABSENCE OF EXOGENOUS IMMUNOSUPPRESSIVE LIGANDS. EMBO JOURNAL, 13(24), 5944-5957.

MOLECULAR ANALYSIS OF THE INTERACTION OF CALCINEURIN WITH DRUG-IMMUNOPHILIN COMPLEXES
Clipstone, N. A., Fiorentino, D. F., & Crabtree, G. R. (1994). MOLECULAR ANALYSIS OF THE INTERACTION OF CALCINEURIN WITH DRUG-IMMUNOPHILIN COMPLEXES. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(42), 26431-26437.

RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE
Kuo, C. J., Chung, J. K., Fiorentino, D. F., Flanagan, W. M., Blenis, J., & Crabtree, G. R. (1992). RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE. NATURE, 358(6381), 70-73.

IL-10 INHIBITS CYTOKINE PRODUCTION BY ACTIVATED MACROPHAGES
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & OGARRA, A. (1991). IL-10 INHIBITS CYTOKINE PRODUCTION BY ACTIVATED MACROPHAGES. JOURNAL OF IMMUNOLOGY, 147(11), 3815-3822.

PRODUCTION OF IL-10 BY CD4+ LYMPHOCYTES-T CORRELATES WITH DOWN-REGULATION OF TH1 CYTOKINE SYNTHESIS IN HELMINTH INFECTION
Sher, A., Fiorentino, D., Caspar, P., Pearce, E., & Mosmann, T. (1991). PRODUCTION OF IL-10 BY CD4+ LYMPHOCYTES-T CORRELATES WITH DOWN-REGULATION OF TH1 CYTOKINE SYNTHESIS IN HELMINTH INFECTION. JOURNAL OF IMMUNOLOGY, 147(8), 2713-2716.

DIVERSITY OF CYTOKINE SYNTHESIS AND FUNCTION OF MOUSE CD4+ T-CELLS
Mosmann, T. R., SCHUMACHER, J. H., STREET, N. F., Budd, R., OGARRA, A., & Fiorentino, D. F. (1991). DIVERSITY OF CYTOKINE SYNTHESIS AND FUNCTION OF MOUSE CD4+ T-CELLS. IMMUNOLOGICAL REVIEWS, 123, 209-229.

IL-10 ACTS ON THE ANTIGEN-PRESENTING CELL TO INHIBIT CYTOKINE PRODUCTION BY TH1 CELLS
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., & OGARRA, A. (1991). IL-10 ACTS ON THE ANTIGEN-PRESENTING CELL TO INHIBIT CYTOKINE PRODUCTION BY TH1 CELLS. JOURNAL OF IMMUNOLOGY, 146(10), 3444-3451.

ISOLATION AND EXPRESSION OF HUMAN CYTOKINE SYNTHESIS INHIBITORY FACTOR CDNA CLONES - HOMOLOGY TO EPSTEIN-BARR-VIRUS OPEN READING FRAME BCRFI
Vieira, P., DEWAALMALEFYT, R., Dang, M. N., Johnson, K. E., Kastelein, R., & Moore, K. W. (1991). ISOLATION AND EXPRESSION OF HUMAN CYTOKINE SYNTHESIS INHIBITORY FACTOR CDNA CLONES - HOMOLOGY TO EPSTEIN-BARR-VIRUS OPEN READING FRAME BCRFI. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 88(4), 1172-1176.

EXPRESSION OF INTERLEUKIN-10 ACTIVITY BY EPSTEIN-BARR-VIRUS PROTEIN BCRF1
Hsu, D. H., Malefyt, R. D., Fiorentino, D. F., Dang, M. N., Vieira, P., & Moore, K. W. (1990). EXPRESSION OF INTERLEUKIN-10 ACTIVITY BY EPSTEIN-BARR-VIRUS PROTEIN BCRF1. SCIENCE, 250(4982), 830-832.

ISOLATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR IL-4, IL-5, IL-6, AND A NEW TH2-SPECIFIC CYTOKINE (IL-10), CYTOKINE SYNTHESIS INHIBITORY FACTOR, BY USING A SOLID-PHASE RADIOIMMUNOADSORBENT ASSAY
Mosmann, T. R., SCHUMACHER, J. H., Fiorentino, D. F., LEVERAH, J., Moore, K. W., & Bond, M. W. (1990). ISOLATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR IL-4, IL-5, IL-6, AND A NEW TH2-SPECIFIC CYTOKINE (IL-10), CYTOKINE SYNTHESIS INHIBITORY FACTOR, BY USING A SOLID-PHASE RADIOIMMUNOADSORBENT ASSAY. JOURNAL OF IMMUNOLOGY, 145(9), 2938-2945.

HOMOLOGY OF CYTOKINE SYNTHESIS INHIBITORY FACTOR (IL-10) TO THE EPSTEIN-BARR-VIRUS GENE BCRFI
Moore, K. W., Vieira, P., Fiorentino, D. F., TROUNSTINE, M. L., Khan, T. A., & Mosmann, T. R. (1990). HOMOLOGY OF CYTOKINE SYNTHESIS INHIBITORY FACTOR (IL-10) TO THE EPSTEIN-BARR-VIRUS GENE BCRFI. SCIENCE, 248(4960), 1230-1234.

HETEROGENEITY OF MOUSE HELPER T-CELLS - EVIDENCE FROM BULK CULTURES AND LIMITING DILUTION CLONING FOR PRECURSORS OF TH1 AND TH2 CELLS
Street, N. E., SCHUMACHER, J. H., Fong, T. At., Bass, H., Fiorentino, D. F., & Mosmann, T. R. (1990). HETEROGENEITY OF MOUSE HELPER T-CELLS - EVIDENCE FROM BULK CULTURES AND LIMITING DILUTION CLONING FOR PRECURSORS OF TH1 AND TH2 CELLS. JOURNAL OF IMMUNOLOGY, 144(5), 1629-1639.

2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES
Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989). 2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES. JOURNAL OF EXPERIMENTAL MEDICINE, 170(6), 2081-2095.

HETEROGENEITY OF MOUSE HELPER T-CELLS AND CROSS-REGULATION OF TH1 AND TH2 CLONES
Mosmann, T. R., Street, N. E., Fiorentino, D. F., Bond, M. W., Fong, T. At., & Moore, K. W. (1989). HETEROGENEITY OF MOUSE HELPER T-CELLS AND CROSS-REGULATION OF TH1 AND TH2 CLONES. SPRINGER-VERLAG BERLIN.

View All 77 Publications